APA (7th ed.) Citation

JC, K., AJ, M., CS, D., SA, W., LM, S., & A, B. (2024). Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: Elacestrant as the poster-child. Expert review of anticancer therapy, 24(6), 397. https://doi.org/10.1080/14737140.2024.2346188

Chicago Style (17th ed.) Citation

JC, Keenan, Medford AJ, Dai CS, Wander SA, Spring LM, and Bardia A. "Novel Oral Selective Estrogen Receptor Degraders (SERDs) to Target Hormone Receptor Positive Breast Cancer: Elacestrant as the Poster-child." Expert Review of Anticancer Therapy 24, no. 6 (2024): 397. https://doi.org/10.1080/14737140.2024.2346188.

MLA (9th ed.) Citation

JC, Keenan, et al. "Novel Oral Selective Estrogen Receptor Degraders (SERDs) to Target Hormone Receptor Positive Breast Cancer: Elacestrant as the Poster-child." Expert Review of Anticancer Therapy, vol. 24, no. 6, 2024, p. 397, https://doi.org/10.1080/14737140.2024.2346188.